Form 4: iRhythm Technologies Director Brian Yoor Acquires 1,358 Restricted Stock Units

iRhythm Technologies, Inc. Director Brian B. Yoor reported the acquisition of 1,358 restricted stock units (RSUs) on May 28, 2025, increasing his direct beneficial ownership to 5,598 shares.

Summary

• Brian B. Yoor, a Director of iRhythm Technologies, Inc. (IRTC), acquired 1,358 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 28, 2025.
• The transaction was an acquisition (A) at a price of $0 per share, which is typical for RSU grants as a form of equity compensation.
• Following this transaction, Mr. Yoor's direct beneficial ownership of iRhythm Technologies Common Stock increased to 5,598 shares.
• Each RSU represents a contingent right to receive one share of IRTC Common Stock.
• The vesting of these RSUs will occur on the earlier of (i) one year after the grant date or (ii) the date of the company's next annual meeting.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a director is generally viewed as a positive signal of alignment with shareholder interests, though it is a routine compensation event and not indicative of extraordinary performance or strategic shifts.

Positives

• The acquisition of restricted stock units by a director aligns their interests with those of shareholders, as the value of their compensation is tied to the company's stock performance.
• Equity grants to directors are a common practice in corporate governance, serving to attract and retain qualified board members.

Future Outlook

The vesting schedule for the acquired Restricted Stock Units indicates future share issuance to the director upon satisfaction of the vesting conditions, which are either one year from the grant date or the date of the company's next annual meeting.

Industry Context

This Form 4 filing details a routine insider transaction, specifically an equity compensation grant to a director. Such grants are standard practice across various industries, particularly in technology and healthcare, to incentivize long-term commitment and align management/board interests with shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common form of non-cash compensation in publicly traded companies, consistent with compensation practices observed in the medical technology and healthcare sectors.
• The vesting schedule, tied to either a one-year period or the next annual meeting, is a typical structure for director equity awards, similar to those seen at companies like Medtronic (MDT) or Boston Scientific (BSX) for their non-employee directors.

Related Party Transactions

• The grant of Restricted Stock Units to Brian B. Yoor, a director of iRhythm Technologies, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decision-making.
• Employees: No direct impact on employees is indicated by this specific filing, as it pertains to director compensation.

Next Steps

• The Restricted Stock Units (RSUs) will vest on the earlier of one year after the grant date or the date of the company's next annual meeting, at which point the director will receive the underlying shares of Common Stock.

Key Dates

Keywords

iRhythm Technologies, IRTC, Form 4, insider transaction, restricted stock units, RSU, equity compensation, director, beneficial ownership